A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

NCT01009424 ·Status: WITHDRAWN ·Phase: PHASE1

Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

NCT02165826 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis

NCT04122547 ·Status: COMPLETED ·Phase: PHASE3

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

NCT02097992 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily

NCT01849341 ·Status: COMPLETED ·Phase: PHASE4

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

NCT00430729 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD

NCT07314242 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

NCT01730404 ·Status: COMPLETED ·Phase: PHASE2

Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease

NCT01509677 ·Status: COMPLETED ·Phase: PHASE3

Roflumilast in Non-CF Bronchiectasis Study (2019)

NCT04322929 ·Status: COMPLETED ·Phase: PHASE2

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

NCT01595750 ·Status: UNKNOWN ·Phase: PHASE4

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

NCT04636814 ·Status: TERMINATED ·Phase: PHASE3

Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis

NCT04090294 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Long-term Observational Study of the Safety of Roflumilast

NCT03381573 ·Status: COMPLETED

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)

NCT00246935 ·Status: COMPLETED ·Phase: PHASE3

Roflumilast in Non-CF Bronchiectasis Study

NCT03428334 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

NCT00242320 ·Status: COMPLETED ·Phase: PHASE3

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

NCT01329029 ·Status: COMPLETED ·Phase: PHASE4

Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

NCT01973998 ·Status: COMPLETED ·Phase: PHASE3

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845 ·Status: COMPLETED ·Phase: PHASE4

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

NCT00076089 ·Status: COMPLETED ·Phase: PHASE3

Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT01473758 ·Status: TERMINATED ·Phase: PHASE2

Study in Patients With COPD

NCT00215423 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.

NCT05426915 ·Status: UNKNOWN

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415 ·Status: COMPLETED ·Phase: PHASE3